Women living with HIV have significantly lower odds of viral suppression when their adherence to antiretroviral therapy is below 90%, a recent study shows.
A recent study found that antiretroviral therapy adherence below 90% was associated with significantly lower odds of viral suppression among women living with HIV .Researchers analyzed data from community-based prospective cohort study including women living with HIV across British Columbia, Ontario, and Quebec between 2013 and 2018.
Overall, 1187 participants who reported antiretroviral therapy use and specified their regimen were included in the analysis. Participants completed questionnaire surveys at three timepoints, at 18 months interval between 2013 and 2018. Analysis focused on the relationship between adherence to antiretroviral therapy and viral suppression using data from the study period between 2017 and 2018.The use of integrase strand transfer inhibitors increased from 13.6% in 2013 to 30.6% in 2018, whereas the utilization of other antiretroviral classes showed declining trends. Among participants, 78.2% reported undetectable viral loads, and viral suppression was achieved by 89.6% of those on regimens consisting of a backbone plus a third agent. Less than 70% adherence and 80%-89% adherence were associated with lower odds of viral suppression compared with ≥ 95% adherence. Researchers found no significant difference in the odds of viral suppression between 90%-94% adherence and ≥ 95% adherence.“With the chronic nature of HIV and the risk of resistance, supporting patients in overcoming the challenges that accompany long-term medication adherence through cotailored approaches should remain a priority when providing care to women living with HIV,” the authors wrote.The study was led by Alexandra de Pokomandy, Department of Family Medicine, McGill University, Montreal, Quebec, Canada. It wasThe study was limited by a small sample size in groups with lower adherence, which may have reduced the statistical power to detect significant differences. All measures were self-reported, introducing social desirability bias and recall bias. The study also lacked information on the status of mental health treatment and the duration of viral suppression. The study received funding from the Canadian Institutes of Health Research, the Canadian HIV Trials Network, the Ontario HIV Treatment Network, and the Ontario Academic Health Science Centers Alternative Funding Plans Innovation. Two authors reported having financial ties with several pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
HIV Disease HIV HIV Antiretroviral Therapy Antiretroviral Therapy For HIV Atazanavir Darunavir Etravirine Tipranavir HIV Therapy HIV ART Adherence Adherence To Medication Issues For Patients Compliance Drug Compliance Treatment Adherence Canada Canadian Artificial Intelligence Deep Learning AI NPL Machine Learning ML Natural Language Processing
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Judge orders involuntary medication of conspiracy theorist charged with killing kids in RosaritoMatthew Coleman immediately appealed, and the order has been paused for now
Read more »
Judge orders involuntary medication of California conspiracy theorist charged with killing his 2 kids in MexicoThe judge immediately paused ruling to give Matthew Coleman time to appeal. Coleman has been found incompetent for trial on charges he killed his two children while paranoid with QAnon and other co…
Read more »
HIV: Genetic characteristics associated with sustained HIV remission after stopping treatmentTackling HIV continues to be a major public health challenge, mainly because the persistence of viral reservoirs means that people living with HIV need to take lifelong antiretroviral treatment. But some individuals, known as 'post-treatment controllers,' are able to maintain an undetectable viral load even after stopping treatment.
Read more »
Haitians with HIV defy stigma as they publicly denounce USAID cuts and dwindling medicationHaitians with HIV are defying stigma as they publicly denounce USAID cuts implemented by the administration of U.S. President Donald Trump that has led to a dwindling of life-saving medication.
Read more »
Haitians with HIV defy stigma as they publicly denounce USAID cuts and dwindling medicationHaitians with HIV are defying stigma as they publicly denounce USAID cuts implemented by the administration of U.S. President Donald Trump that has led to a dwindling of life-saving medication.
Read more »
Haitians with HIV defy stigma as they publicly denounce USAID cuts and dwindling medicationHaitians with HIV are defying stigma as they publicly denounce USAID cuts implemented by the administration of U.S. President Donald Trump that has led to a dwindling of life-saving medication.
Read more »